The Government receives some proposals of Asebio to enrich the Plan Profarma

The Spanish Association of Bioempresas (Asebio) values of positive form that the Government have received some of his proposals presented to enrich the Plan Profarma.

During SAW it Annual Conference of the Technological Platforms of Investigation Biomédica: ‘Innovative Medicines, Nanomedicina, Sanitary ware Technology and Markets Biotecnológicos' celebrated in March in Madrid, the president of Asebio, Regina Revilla, did a call to the Government so that it reviewed the Plan Profarma with the aim that the sector biotecnológico had greater weight.

The BOE finishes to publish the announcement of the Plan Profarma that goes headed to the companies of the pharmaceutical sector, situated in Spain, that manufacture or commercialise medicines of human use and that realizar activities of pharmaceutical R&D in the national territory. This program has like fundamental aim increase the competitiveness of the pharmaceutical industry in Spain, through the modernisation of the sector and the potenciación of those activities that contribute a greater value added.

Asebio Has kept diverse meetings with the Executive with the aim that the Plan Profarma will adapt more to the reality of the sector biotecnológico Spanish. Like novelties, on request of Asebio, will evaluate the realisation of clinical essays in Spain, particularly in the earliest phases and the costs in R&D.

This measure is especially notable for Asebio, since there is a big number of companies biotecnológicas initiating the clinical development of his molecules.

The pipeline of sanitary ware biotechnology of Asebio collects 357 projects. Of them, 209 indications are of medicines investigated in Spain that still are not commercialising, pertaining so much to national entities as to subsidiaries of multinationals. Between the 209 indications, exist 104 products for 119 clinical indications that are investigating 38 national companies, 56 of them find in phase preclínica, 22 in phase I, 31 in phase II, five in phase III and five are smart to commercialise . Besides, they exist 90 clinical indications of 83 products of the area of medicines of seven multinationals with subsidiary in Spain, in which any of his clinical phases has realizar in Spain. One of them are in phase I, 28 in phase II, 48 in phase III and 13 are smart to commercialise .

This year, includes a classification of the companies in these groups:

Group To: Companies with activity significant researcher with own plant of pharmaceutical production or centre typical of basic R&D or preclínica.

Group B: Companies with own plant of pharmaceutical production and that realizar some activities of R&D, like technological development, but do not reach the level of significant.

Group C: Companies without plant of pharmaceutical production but with activity of own R&D or hired in national territory.

The companies that do not reach the minimum punctuation that establishes the Committee of Coordination to be described, will be considered ‘no valued'.

Although the measures adopted and/or announced suppose an advance, the patronal considers that still there is a big area of improvement to favour the development of the industry biomédica in our country. In particular, for next announcements of the Plan Profarma, Asebio proposes that they take into account with maximum assessment the financial operations of total or partial acquisition of SMEs biotech by part of pharmaceutical laboratories.